1. Overview and Insights into Carbapenem Allergy
- Author
-
Yuman Lee and Nicole Bradley
- Subjects
0301 basic medicine ,Imipenem ,medicine.medical_specialty ,Carbapenem ,030106 microbiology ,lcsh:RS1-441 ,doripenem ,Review ,Meropenem ,carbapenem ,lcsh:Pharmacy and materia medica ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,ertapenem ,meropenem ,medicine ,polycyclic compounds ,Pharmacology (medical) ,General Pharmacology, Toxicology and Pharmaceutics ,Intensive care medicine ,Cilastatin ,business.industry ,Imipenem/cilastatin ,biochemical phenomena, metabolism, and nutrition ,bacterial infections and mycoses ,allergy ,Penicillin ,030228 respiratory system ,chemistry ,imipenem/cilastatin ,Doripenem ,bacteria ,cross-sensitivity ,business ,Ertapenem ,medicine.drug - Abstract
Understanding antibiotic allergies and the risk of cross-sensitivity between and within antibiotic classes can have a substantial impact on patient care. The purpose of this review article is to provide insight into carbapenem allergies, describing the overall incidence, risk factors, and in-class cross-sensitivity. A PubMed search was conducted using the following search terms: carbapenem, allergy, cross-sensitivity, incidence, imipenem/cilastatin, meropenem, ertapenem, and doripenem. Article bibliographies and relevant drug monographs were also reviewed. The overall reported incidence of carbapenem allergy is 0.3%–3.7%. Risk of cross-sensitivity between penicillins and carbapenems is less than 1% in patients with a positive penicillin skin test. Data on cross-sensitivity between cephalosporins and carbapenems are limited; however, the risk appears to also be low. No clinical studies have described cross-sensitivity between the carbapenem agents thus far. The limited data available from case reports demonstrates a lack of cross-sensitivity between the individual carbapenems, suggesting that an alternative carbapenem may cautiously be used in patients with a reported carbapenem allergy.
- Published
- 2019